Biosimilar Contract Manufacturing Market Size, Share and Growth Outlook, 2026

Biosimilar Contract Manufacturing Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Biosimilar Contract Manufacturing Market size is forecast to increase from $10.6 Billion in 2026 to $30.66 Billion in 2034 at a CAGR of 14.2% between 2026 and 2034.

The Biosimilar Contract Manufacturing market report provides detailed analysis and outlook of Biosimilar Contract Manufacturing segments including By Service Type (Upstream Processing, Downstream Processing, Process Development, Bioassay & Biosimilarity Testing, Fill & Finish Operations), By Expression System (Mammalian Systems, Microbial Systems, Others ), By Product Type (Monoclonal Antibodies, Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins ), By Application (Oncology, Chronic & Autoimmune Disorders, Blood Disorders, Infectious Diseases, Metabolic Disorders) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Biosimilar Contract Manufacturing Industry Overview

Growing Reliance on CDMO Partnerships for Complex Biologic Production

The biosimilar contract manufacturing industry is becoming increasingly important as pharmaceutical and biotechnology companies seek specialized manufacturing expertise to support the development and commercialization of complex biologics. Contract development and manufacturing organizations (CDMOs) are expanding their capabilities beyond traditional biologics production to accommodate advanced therapeutic modalities and highly specialized manufacturing requirements. A notable example is Catalent, which entered multiple global partnerships to strengthen its advanced manufacturing portfolio. The company established collaborations with Elpida Therapeutics for late-phase adeno-associated virus (AAV) manufacturing and with S.Biomedics for pluripotent stem-cell-derived therapies. These partnerships demonstrate how CDMOs are increasingly serving as strategic outsourcing partners for sophisticated biologic pipelines, while also building infrastructure and technical expertise that can be leveraged across biosimilar manufacturing programs. The growing complexity of biologics production is driving demand for integrated development, process optimization, and commercial-scale manufacturing services.

Advanced Purification Technologies Enhancing Biosimilar Manufacturing Efficiency

Process optimization remains a major focus within the biosimilar contract manufacturing industry as companies work to improve productivity, reduce development timelines, and accelerate regulatory readiness. Catalent expanded its manufacturing technology portfolio through the introduction of the ShunzymeX precision purification platform. This advanced downstream processing technology is specifically designed to streamline process development and accelerate Good Manufacturing Practice (GMP) preparedness for complex biologics. By improving purification efficiency and supporting faster manufacturing scale-up, ShunzymeX addresses critical industry challenges associated with biosimilar production, including process consistency, product quality, and regulatory compliance. As biosimilar developers seek cost-effective pathways to commercialization, innovations in purification technologies are becoming essential components of modern contract manufacturing operations.

Sustainability Initiatives Reshaping Contract Manufacturing Operations

Environmental responsibility is emerging as a key competitive factor within the biosimilar contract manufacturing industry. Manufacturers are increasingly integrating sustainability programs into production operations while maintaining the quality and reliability required for biosimilar medicines. Samsung Biologics demonstrated this trend by receiving the Sustainability Leadership Award at the CDMO Leadership Awards. The company implemented an independently validated Product Carbon Footprint (PCF) system and achieved an EcoVadis Platinum rating, reflecting its commitment to transparent environmental performance. These initiatives align with broader industry efforts to reduce manufacturing-related emissions, improve resource efficiency, and enhance sustainability reporting across biologics production networks. As pharmaceutical companies place greater emphasis on environmental, social, and governance objectives, sustainable manufacturing practices are becoming an increasingly important consideration when selecting biosimilar contract manufacturing partners.

Biosimilar Contract Manufacturing Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Biosimilar Contract Manufacturing market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Samsung Biologics Co., Ltd., Lonza Group AG, WuXi Biologics (Cayman) Inc., Catalent, Inc. (Novo Holdings), Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Biocon Biologics Ltd., Merck KGaA, Rentschler Biopharma SE, Almac Group Limited. The Biosimilar Contract Manufacturing market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Biosimilar Contract Manufacturing industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Biosimilar Contract Manufacturing Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Biosimilar Contract Manufacturing companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Biosimilar Contract Manufacturing markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Biosimilar Contract Manufacturing Market Competitive Benchmarking and Company Analysis

Leading companies in Biosimilar Contract Manufacturing industry include- Samsung Biologics Co., Ltd., Lonza Group AG, WuXi Biologics (Cayman) Inc., Catalent, Inc. (Novo Holdings), Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Biocon Biologics Ltd., Merck KGaA, Rentschler Biopharma SE, Almac Group Limited. The Biosimilar Contract Manufacturing market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Biosimilar Contract Manufacturing Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Biosimilar Contract Manufacturing market remains one of the strongest-performing segments in the country.
The US Biosimilar Contract Manufacturing Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Biosimilar Contract Manufacturing market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Biosimilar Contract Manufacturing industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Biosimilar Contract Manufacturing markets

Canada's strong Biosimilar Contract Manufacturing sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Biosimilar Contract Manufacturing market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Biosimilar Contract Manufacturing Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Biosimilar Contract Manufacturing market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Biosimilar Contract Manufacturing population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Biosimilar Contract Manufacturing industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Biosimilar Contract Manufacturing market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Biosimilar Contract Manufacturing sales through 2034

France Biosimilar Contract Manufacturing companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Biosimilar Contract Manufacturing Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Biosimilar Contract Manufacturing distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Biosimilar Contract Manufacturing Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Biosimilar Contract Manufacturing market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Biosimilar Contract Manufacturing industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Biosimilar Contract Manufacturing industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Biosimilar Contract Manufacturing Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Biosimilar Contract Manufacturing market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Biosimilar Contract Manufacturing market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Biosimilar Contract Manufacturing Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Biosimilar Contract Manufacturing Market Segmentation

By Service Type
Upstream Processing
Downstream Processing
Process Development
Bioassay & Biosimilarity Testing
Fill & Finish Operations
By Expression System
Mammalian Systems
Microbial Systems
Others
By Product Type
Monoclonal Antibodies
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
By Application
Oncology
Chronic & Autoimmune Disorders
Blood Disorders
Infectious Diseases
Metabolic Disorders

Top Companies in Biosimilar Contract Manufacturing Industry

Samsung Biologics Co., Ltd.
Lonza Group AG
WuXi Biologics (Cayman) Inc.
Catalent, Inc. (Novo Holdings)
Boehringer Ingelheim International GmbH
Fujifilm Diosynth Biotechnologies
Biocon Biologics Ltd.
Merck KGaA
Rentschler Biopharma SE
Almac Group Limited

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025